Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Airdoc Technology Co., Ltd. (2251.HK)
Beijing, JS, CN
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.81% | +0.39% | -14.06% | -11.91% | -13.77% | -10.67% | -14.20% | -1.64% | -84.99% | -84.99% | -84.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+10.8% ★ Q4'25: -26.3% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+90.4% ★ Q4'25: +76.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-24.0% Q4'25: -2.3% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-16.3% Q4'25: -20.1% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-4.7% Q4'25: -10.5% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.1% Q4'25: -0.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-3.37× Q4'25: -0.85× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
115.18M
est: 113.21M (+1.7%)
|
113.66M
est: 158.13M (-28.1%)
|
203.96M
est: 200.15M (+1.9%)
|
156.37M
est: 242.41M (-35.5%)
|
173.26M
est: 198.80M (-12.8%)
|
260.92M
260.92M – 260.92M
+31.2% YoY
|
889.64M
889.64M – 889.64M
+241.0% YoY
|
| EBITDA |
-126.73M
est: -103.15M (-22.9%)
|
-159.64M
est: -144.08M (-10.8%)
|
-113.36M
est: -144.19M (+21.4%)
|
-259.70M
est: -174.63M (-48.7%)
|
-8.00M
est: -143.21M (+94.4%)
|
-187.97M
-187.97M – -187.97M
-31.2% YoY
|
-640.89M
-640.89M – -640.89M
-241.0% YoY
|
| EBIT |
-142.23M
est: -106.70M (-33.3%)
|
-182.30M
est: -149.04M (-22.3%)
|
-145.31M
est: -155.14M (+6.3%)
|
-283.18M
est: -187.89M (-50.7%)
|
-28.24M
est: -154.09M (+81.7%)
|
-202.24M
-202.24M – -202.24M
-31.2% YoY
|
-689.55M
-689.55M – -689.55M
-241.0% YoY
|
| Net Income |
-142.63M
est: -136.71M (-4.3%)
|
-180.00M
est: -145.24M (-23.9%)
|
-132.53M
est: -162.93M (+18.7%)
|
-255.46M
est: -91.99M (-177.7%)
|
-24.98M
est: -117.54M (+78.8%)
|
-39.24M
-39.24M – -39.24M
+66.6% YoY
|
77.34M
77.34M – 77.34M
+297.1% YoY
|
| SGA |
149.65M
est: 130.57M (+14.6%)
|
180.08M
est: 182.38M (-1.3%)
|
199.63M
est: 226.84M (-12.0%)
|
186.81M
est: 274.72M (-32.0%)
|
105.60M
est: 225.30M (-53.1%)
|
295.71M
295.71M – 295.71M
+31.2% YoY
|
1.01B
1.01B – 1.01B
+241.0% YoY
|
| EPS |
-1.76
est: -1.34 (-31.6%)
|
-1.75
est: -1.42 (-23.1%)
|
-1.28
est: -1.59 (+19.7%)
|
-2.50
est: -0.90 (-177.9%)
|
-0.24
est: -1.15 (+79.1%)
|
-0.38
-0.38 – -0.38
+66.6% YoY
|
0.76
0.76 – 0.76
+297.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao He | Chief Technology Officer | 2M | — |
| Yong Qin | Executive Director & Secretary to the Board | 1M | male |
| Lin Wang | Executive Director & General Counsel | 876.4K | female |
| Yubo Wei | Executive Director | 566.9K | male |
| Dalei Zhang | GM, Chief Executive Officer & Executive Chairman | 542.7K | male |
| Lai Shan So | Joint Company Secretary | — | female |
| Xinfeng Wang | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2251.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
